Effective vaccines against COVID-19 are urgently needed to control the global pandemic. More than 280 candidate vaccines are in development worldwide, 23 of which are already in phase 3 trials using different platforms.
In this phase 3 randomized trial in adults, 2 whole-virus inactivated vaccines showed efficacy of 72.8% and 78.1% against symptomatic COVID-19 cases. The 2 vaccines had rare serious adverse events at a frequency similar to the alum-only control and the majority were not related to the vaccines. 2 vaccines induced measurable, neutralizing antibodies, similar to results in the phase 1 [and] 2 trials.
In this… interim analysis of a randomized clinical trial, treatment of adults with either of 2 inactivated SARS-CoV-2 vaccines significantly reduced the risk of symptomatic COVID-19… final analysis is pending.“Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults” – Nawal Al Kaabi, MBBS et al. (JAMA Network)
Inactivated vaccines is one platform that has been extensively studied as they are generally safe and widely used for the prevention of respiratory infections such as influenza and are easily stored/shipped. Another great research article, and evidence of researchers working day and night to keep us safe and prevent the spread of this invisible enemy.
Stay informed, stay well, and stay tuned!